MedTrace Logo

Scandinavian Candesartan Acute Stroke Trial (SCAST)

NCT00120003 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2500

Last updated 2011-07-01

No results posted yet for this study

Summary

The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure.

Hypothesis:

AT1 receptor blockade with candesartan in acute stroke will:

1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo.
2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo

Conditions

Interventions

DRUG

Candesartan Cilexetil

4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7

DRUG

Placebo

4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7

Sponsors & Collaborators

  • Southern-Eastern Norway Health Authorities RHF

    collaborator UNKNOWN

  • AstraZeneca

    collaborator INDUSTRY

  • Takeda

    collaborator INDUSTRY

  • Ullevaal University Hospital

    lead OTHER

Principal Investigators

  • Eivind Berge, MD, PhD · Ullevaal University Hospital

  • Per Morten Sandset, Prof · Ullevaal University Hospital

  • Povel Paus, MD, PhD · Ullevaal University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120003 on ClinicalTrials.gov